Can I Take Phentermine and Mounjaro Together? The Evidence-Based Answer and Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No published clinical trials have tested phentermine combined with tirzepatide (Mounjaro), and most providers avoid this combination due to overlapping cardiovascular risks and lack of safety data
• Phentermine increases heart rate and blood pressure through sympathomimetic stimulation, while tirzepatide already carries a small tachycardia signal, creating additive cardiovascular stress
• The combination offers no proven benefit over tirzepatide alone, which produces 15-21% total body weight loss in published trials without needing a stimulant
• If a provider prescribes both medications together, strict cardiovascular monitoring (weekly BP and HR checks for the first month) and immediate discontinuation protocols are required

Direct answer (40-60 words)

There are no published clinical trials testing phentermine combined with Mounjaro (tirzepatide), and most providers avoid this combination. Both medications affect cardiovascular function, phentermine raises heart rate and blood pressure through sympathomimetic stimulation, and tirzepatide already produces substantial weight loss without requiring a stimulant. The risk-benefit calculation favors tirzepatide monotherapy.

Table of contents

1. Why this question comes up: the phentermine legacy
2. The mechanism problem: overlapping cardiovascular effects
3. What the published evidence actually shows (and doesn't show)
4. The cardiovascular monitoring protocol if both are prescribed
5. Why most providers choose tirzepatide alone
6. The specific scenarios where combination therapy gets considered
7. What most articles get wrong about GLP-1 and stimulant combinations
8. The FormBlends clinical pattern: what we see in refill data
9. The decision tree: should you ask your provider about adding phentermine?
10. When phentermine makes sense and when it doesn't
11. The alternative combinations with better evidence
12. FAQ
13. Sources
14. Footer disclaimers

Why this question comes up: the phentermine legacy

Phentermine has been FDA-approved for short-term weight loss (up to 12 weeks) since 1959. It's the most-prescribed weight-loss medication in the United States by volume, largely because it's inexpensive (often under $30 per month), available as a generic, and produces rapid initial results. Patients lose an average of 3-5% of body weight in the first month, mostly through appetite suppression and increased energy expenditure.

The medication works through sympathomimetic stimulation. It releases norepinephrine in the hypothalamus, which suppresses appetite, and increases circulating catecholamines, which raise metabolic rate. The effect feels similar to low-dose amphetamine, which makes sense because phentermine is structurally related to amphetamine.

The question "Can I add phentermine to Mounjaro?" typically comes from one of three situations:

1. Patients already on phentermine who start tirzepatide. They've been taking phentermine for months or years (often off-label beyond the 12-week FDA indication), it's still working, and they want to add a GLP-1 medication for additional weight loss.

1. Patients on tirzepatide who hit a plateau. Weight loss slows after 6-9 months, and they're looking for something to restart progress.

1. Patients who want faster results. Tirzepatide produces steady weight loss over 6-12 months, but phentermine produces noticeable appetite suppression within 48 hours. The desire to combine them is understandable.

The problem is that the combination has never been studied in a controlled trial, and the theoretical risks are significant enough that most providers say no.

The mechanism problem: overlapping cardiovascular effects

Phentermine's cardiovascular effects are well-documented:

• Heart rate increase: Average 5-10 bpm increase in resting heart rate (Hendricks et al., Obesity 2011)
• Blood pressure increase: Systolic BP rises 2-8 mmHg on average, diastolic 1-5 mmHg (Hendricks et al., Obesity 2011)
• Arrhythmia risk: Case reports of atrial fibrillation, ventricular ectopy, and palpitations in susceptible patients
• Sympathetic overdrive: Anxiety, insomnia, tremor, dry mouth

Tirzepatide's cardiovascular profile is different but not neutral:

• Heart rate increase: The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed a mean heart rate increase of 1.7 bpm at 15 mg dose, with 3.5% of patients experiencing clinically significant tachycardia (HR >100 bpm)
• Blood pressure decrease: Tirzepatide lowers systolic BP by 5-7 mmHg on average through weight loss and natriuretic effects, which partially offsets phentermine's hypertensive effect
• No arrhythmia signal: The SURPASS trials showed no increased arrhythmia risk compared to placebo

The concern is additive tachycardia. If phentermine raises your heart rate by 8 bpm and tirzepatide raises it by 2 bpm, you're looking at a 10 bpm increase from baseline. For a patient with a resting HR of 75 bpm, that puts them at 85 bpm, which is still normal. For a patient starting at 85 bpm, that puts them at 95 bpm, approaching tachycardia threshold.

The blood pressure effects partially cancel out, but not reliably. Some patients experience net hypertension, others net hypotension. The variability makes monitoring essential.

What the published evidence actually shows (and doesn't show)

Studies that exist:

1. Phentermine monotherapy. Multiple RCTs showing 3-10% weight loss over 12 weeks to 12 months (Hendricks et al., Obesity 2011; Aronne et al., Obesity 2013). Cardiovascular safety established in patients without pre-existing heart disease.

1. Tirzepatide monotherapy. SURMOUNT-1 and SURMOUNT-2 trials showing 15-21% weight loss over 72 weeks (Jastreboff et al., NEJM 2022; Garvey et al., Lancet 2023). Cardiovascular safety established, with SURPASS-CVOT ongoing.

1. Phentermine combined with topiramate (Qsymia). FDA-approved combination. Multiple RCTs showing 10-12% weight loss over 56 weeks (Gadde et al., Lancet 2011; Garvey et al., Obesity 2012). Cardiovascular monitoring required.

1. Semaglutide (Wegovy) combined with other agents. The STEP 5 trial tested semaglutide alone (no combination arms). No published trials combining semaglutide with phentermine.

Studies that do NOT exist:

• Phentermine combined with any GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, tirzepatide)
• Phentermine combined with any GIP receptor agonist
• Head-to-head comparison of tirzepatide monotherapy vs tirzepatide plus phentermine

The absence of evidence is not evidence of safety. The FDA has not reviewed this combination. No institutional review board has approved a trial protocol testing it. Providers who prescribe both medications together are practicing off-label without safety data.

The cardiovascular monitoring protocol if both are prescribed

If a provider decides the potential benefit outweighs the risk and prescribes both medications, the minimum monitoring protocol is:

Baseline (before starting combination):

• Resting heart rate and blood pressure (sitting, after 5 minutes of rest)
• ECG if patient is over 50, has any cardiac history, or has baseline HR >85 bpm
• Comprehensive metabolic panel (electrolytes, kidney function)
• Thyroid function (TSH) to rule out hyperthyroidism as a cause of baseline tachycardia

Week 1, 2, 3, and 4:

• Home blood pressure and heart rate monitoring twice daily (morning and evening)
• Patient logs symptoms: palpitations, chest discomfort, dizziness, anxiety, insomnia
• Provider review of logs weekly

Month 2 and 3:

• In-office BP and HR check every 2 weeks
• Symptom review

Ongoing (month 4+):

• Monthly BP and HR checks
• Immediate discontinuation if:
• Resting HR sustained above 100 bpm
• Systolic BP above 140 mmHg or diastolic above 90 mmHg on two consecutive readings
• New-onset palpitations, chest pain, or syncope
• Severe anxiety or insomnia interfering with daily function

Discontinuation protocol:

• Stop phentermine first (it has the shorter half-life and more direct cardiovascular effects)
• Continue tirzepatide if weight-loss goals are not yet met
• Recheck BP and HR 7 days after stopping phentermine
• If cardiovascular parameters normalize, continue tirzepatide monotherapy

This protocol is more intensive than standard tirzepatide monitoring because the combination introduces risk that neither medication carries alone.

Why most providers choose tirzepatide alone

The clinical calculus is straightforward: tirzepatide produces 15-21% total body weight loss in published trials without requiring a stimulant. The SURMOUNT-1 trial showed:

Dose	Mean weight loss at 72 weeks	% achieving ≥20% weight loss
Tirzepatide 5 mg	15.0%	30%
Tirzepatide 10 mg	19.5%	50%
Tirzepatide 15 mg	20.9%	57%
Placebo	3.1%	3%

These results exceed what phentermine monotherapy produces (3-10% weight loss) and approach what phentermine-topiramate produces (10-12% weight loss). The question becomes: what additional benefit does phentermine provide?

The theoretical benefit is faster initial appetite suppression. Tirzepatide takes 4-8 weeks to reach steady-state appetite effects. Phentermine works within 48 hours. For patients who struggle with adherence during the first month of GLP-1 therapy, phentermine could bridge the gap.

The problem is that this benefit is speculative. No trial has tested it. And the cardiovascular risk is real, not speculative.

Most providers follow a simple decision rule: if tirzepatide alone produces 15-21% weight loss with a well-characterized safety profile, adding phentermine introduces risk without proven incremental benefit. The risk-benefit ratio favors monotherapy.

The specific scenarios where combination therapy gets considered

There are three narrow scenarios where a provider might consider prescribing both medications:

Scenario 1: Patient already stable on phentermine, adding tirzepatide.

A patient has been taking phentermine for 6-12 months (off-label, but common in clinical practice), tolerates it well, has stable cardiovascular parameters, and wants to add tirzepatide for additional weight loss. The provider may continue phentermine during tirzepatide titration, then taper phentermine once tirzepatide reaches maintenance dose.

The rationale: phentermine is already on board and tolerated. The incremental risk of adding tirzepatide is smaller than starting both simultaneously.

Scenario 2: Tirzepatide plateau after 9-12 months.

A patient loses 18% of body weight on tirzepatide over 9 months, then weight loss stalls for 8-12 weeks despite consistent adherence. The provider may add phentermine for 8-12 weeks to restart progress, then discontinue it once weight loss resumes.

The rationale: short-term phentermine use (the FDA-approved indication) to break a plateau, not long-term combination therapy.

Scenario 3: Patient with contraindication to higher tirzepatide doses.

A patient experiences intolerable nausea at 7.5 mg tirzepatide, cannot escalate to 10 or 15 mg, but needs more weight loss for medical reasons (pre-surgical weight loss, diabetes control). The provider may add phentermine to the tolerated 5 mg tirzepatide dose.

The rationale: phentermine provides additional efficacy without escalating the tirzepatide dose that's causing side effects.

All three scenarios require the cardiovascular monitoring protocol above. None are standard of care. All are off-label clinical judgment calls.

What most articles get wrong about GLP-1 and stimulant combinations

Most online articles addressing this question make one of three errors:

Error 1: "There's no interaction, so it's safe."

The absence of a pharmacokinetic interaction (phentermine doesn't change tirzepatide blood levels, and vice versa) does not mean the combination is safe. The concern is pharmacodynamic: both medications affect cardiovascular function through different mechanisms, and the effects may be additive.

A pharmacokinetic interaction would show up as altered drug levels. A pharmacodynamic interaction shows up as altered physiological response. The latter is the concern here.

Error 2: "Doctors prescribe it all the time, so it must be fine."

Frequency of prescribing is not evidence of safety. Phentermine is prescribed off-label for long-term use despite FDA approval for only 12 weeks. That doesn't make long-term use evidence-based. It means providers are making individual risk-benefit decisions in the absence of data.

The combination is prescribed, but not commonly, and not by most obesity medicine specialists. The providers who prescribe it tend to be in cash-pay weight-loss clinics with less rigorous safety protocols.

Error 3: "If you have side effects, just stop one of the medications."

This is true but incomplete. The question is not whether you can stop if problems arise. The question is whether you should start both in the first place given the lack of evidence and the known cardiovascular risks.

The correct framing is: the combination may be prescribed in specific scenarios with intensive monitoring, but it is not standard of care and carries risks that monotherapy does not.

The FormBlends clinical pattern: what we see in refill data

FormBlends connects patients with providers who prescribe compounded semaglutide and tirzepatide. We do not prescribe phentermine (it is not available as a compounded medication and is outside our clinical model). This gives us a natural experiment: patients on GLP-1 monotherapy without stimulant combination.

The pattern we see across tirzepatide refill data:

• Month 1-3: Patients report appetite suppression within 7-14 days of starting 2.5 mg tirzepatide. The effect is not as immediate as phentermine (which works in 48 hours), but it is noticeable within the first 2 weeks for most patients.

• Month 4-6: Weight loss accelerates as patients reach 7.5-10 mg maintenance doses. The most common refill question during this window is not "Can I add something else?" but "Should I stay at this dose or escalate?"

• Month 7-12: Weight loss continues but slows. Patients who lose 15-20% of body weight in the first 9 months often experience a 2-3 month plateau. The refill pattern shows that most patients stay on tirzepatide through the plateau rather than adding other medications.

• Month 13+: Long-term refill adherence is high (above 80% at 12 months) among patients who tolerate the medication. The patients who discontinue tend to do so because of side effects (nausea, reflux) or cost, not because of inadequate weight loss.

The clinical takeaway: tirzepatide monotherapy produces sustained appetite suppression and weight loss without requiring a stimulant. The patients who ask about adding phentermine are usually in month 1-2 (before tirzepatide has reached full effect) or month 9-12 (plateau phase). In both cases, the pattern suggests patience with tirzepatide monotherapy is more effective than adding phentermine.

This is observational data from refill patterns, not a controlled trial, but it reflects real-world clinical practice across more than 1,000 patient-months of tirzepatide use.

The decision tree: should you ask your provider about adding phentermine?

Start here: Are you currently taking phentermine?

• Yes, and it's working well: Ask your provider about continuing phentermine during tirzepatide titration, with a plan to taper phentermine after 8-12 weeks once tirzepatide reaches maintenance dose. Expect intensive cardiovascular monitoring.

• Yes, but it's not working or causing side effects: Stop phentermine and start tirzepatide alone. Phentermine's effectiveness decreases over time (tachyphylaxis), and if it's not working now, combining it with tirzepatide is unlikely to help.

• No, never taken it: Continue to next question.

Have you been on tirzepatide for at least 12 weeks at a stable maintenance dose (7.5 mg or higher)?

• No, still titrating: Do not add phentermine. Tirzepatide has not reached full effect yet. Most patients see appetite suppression improve significantly between 5 mg and 10 mg. Adding phentermine during titration introduces cardiovascular risk before you know whether tirzepatide alone will work.

• Yes, at maintenance dose for 12+ weeks: Continue to next question.

Has your weight been stable (less than 2 pounds change) for 8+ consecutive weeks despite consistent adherence?

• No, still losing weight: Do not add phentermine. If tirzepatide is still working, there is no reason to add cardiovascular risk.

• Yes, true plateau for 8+ weeks: Continue to next question.

Do you have any of the following cardiovascular conditions?

• Uncontrolled hypertension (BP consistently above 140/90)
• Resting heart rate above 90 bpm
• History of arrhythmia, atrial fibrillation, or palpitations
• History of heart attack, stroke, or coronary artery disease
• Currently taking other stimulant medications (ADHD medications, decongestants, caffeine pills)

• Yes to any: Do not add phentermine. The cardiovascular risk is too high. Discuss alternative options with your provider (dose escalation if not at 15 mg, switching to semaglutide, adding metformin, dietary changes).

• No to all: You may be a candidate for short-term phentermine (8-12 weeks) to break the plateau. Ask your provider. Expect intensive monitoring and a plan to discontinue phentermine once weight loss resumes.

When phentermine makes sense and when it doesn't

Phentermine makes sense:

• Short-term use (8-12 weeks) to jump-start weight loss before bariatric surgery or another medical deadline
• Patients who have used it successfully in the past without cardiovascular side effects
• Breaking a true plateau (8+ weeks of stable weight) after 6-9 months of tirzepatide
• Patients who cannot tolerate higher tirzepatide doses due to GI side effects but need more weight loss

Phentermine does NOT make sense:

• Long-term combination therapy (beyond 12 weeks)
• Patients with any cardiovascular risk factors
• Patients in the first 12 weeks of tirzepatide titration
• Patients who are still losing weight on tirzepatide alone
• Patients taking other stimulant medications
• Patients with anxiety, insomnia, or other conditions worsened by sympathomimetic stimulation
• Patients over 65 (higher cardiovascular risk)

The FDA approved phentermine for short-term use in 1959. The "short-term" designation was not arbitrary. It reflects the fact that phentermine's effectiveness decreases over time (tolerance develops) and cardiovascular risks accumulate with longer use.

Combining phentermine with tirzepatide does not change phentermine's risk profile. If anything, it increases risk through additive cardiovascular effects.

The alternative combinations with better evidence

If you are on tirzepatide and want to add something to enhance weight loss, several options have better evidence than phentermine:

Metformin (off-label for weight loss).

• Mechanism: Reduces hepatic glucose production, improves insulin sensitivity, modest appetite suppression
• Weight loss: 2-3% additional weight loss when added to lifestyle intervention (Diabetes Prevention Program, NEJM 2002)
• Safety: Well-tolerated, no cardiovascular risk, decades of safety data
• Combination with tirzepatide: No published trials, but no theoretical safety concern

Topiramate (off-label for weight loss).

• Mechanism: Modulates GABA and glutamate, reduces appetite, increases satiety
• Weight loss: 5-7% when used alone (Bray et al., Obesity Research 2003)
• Safety: Cognitive side effects (word-finding difficulty, memory issues) limit use; contraindicated in pregnancy
• Combination with tirzepatide: No published trials, theoretical safety concern around cognitive effects

Naltrexone-bupropion (Contrave, FDA-approved).

• Mechanism: Naltrexone blocks opioid receptors, bupropion inhibits dopamine and norepinephrine reuptake, combined effect reduces food reward and cravings
• Weight loss: 5-9% over 56 weeks (Greenway et al., Lancet 2010)
• Safety: Contraindicated in uncontrolled hypertension, seizure disorders; black box warning for neuropsychiatric effects
• Combination with tirzepatide: No published trials, no obvious safety concern but also no proven benefit

Orlistat (Alli, Xenical, FDA-approved).

• Mechanism: Lipase inhibitor, blocks absorption of dietary fat
• Weight loss: 3-5% over 12 months (Torgerson et al., Diabetes Care 2004)
• Safety: GI side effects (oily stools, fecal urgency) limit adherence
• Combination with tirzepatide: No safety concern, but GI side effects of both medications may be additive

None of these combinations have been tested in rigorous trials with tirzepatide. The difference is that none carry the same cardiovascular risk signal that phentermine does. Metformin is the most commonly added medication in clinical practice because of its safety profile and metabolic benefits beyond weight loss.

FAQ

Can I take phentermine and Mounjaro at the same time? Technically yes, but no published studies have tested this combination, and most providers avoid it due to overlapping cardiovascular effects. Phentermine raises heart rate and blood pressure, and tirzepatide carries a small tachycardia signal. If both are prescribed, intensive cardiovascular monitoring is required.

Is it safe to combine phentermine with tirzepatide? The combination has not been studied in clinical trials, so safety is unknown. Both medications affect heart rate, and the effects may be additive. Patients with pre-existing cardiovascular conditions should not combine them. Healthy patients may tolerate the combination with close monitoring, but the risk-benefit ratio favors tirzepatide alone.

Will adding phentermine to Mounjaro help me lose more weight? There is no evidence that the combination produces more weight loss than tirzepatide alone. Tirzepatide produces 15-21% total body weight loss in published trials, which exceeds what phentermine monotherapy achieves. The theoretical benefit of faster initial appetite suppression has not been proven.

What are the risks of taking phentermine and Mounjaro together? The primary risks are increased heart rate (tachycardia), elevated blood pressure, palpitations, anxiety, and insomnia. Both medications can cause these effects independently, and combining them may make them worse. Patients over 50 or with any cardiac history face higher risk.

How long can I take phentermine with tirzepatide? Phentermine is FDA-approved for short-term use only (up to 12 weeks). If a provider prescribes both medications together, phentermine should be discontinued after 8-12 weeks, not continued indefinitely. Long-term combination therapy has no safety data.

Should I start both medications at the same time? No. If you are not currently taking phentermine, start tirzepatide alone and allow 12-16 weeks to reach maintenance dose and assess response. Adding phentermine during titration introduces risk before you know whether tirzepatide alone will work.

Can I take phentermine if I'm already on compounded tirzepatide? Compounded tirzepatide has the same active ingredient and mechanism as brand-name Mounjaro. The same safety considerations apply. Discuss with your prescribing provider, and expect cardiovascular monitoring if both are prescribed.

What should I monitor if my doctor prescribes both medications? Check blood pressure and heart rate twice daily for the first month. Log any symptoms of palpitations, chest discomfort, dizziness, or anxiety. Report sustained heart rate above 100 bpm or blood pressure above 140/90 mmHg immediately. Your provider should see you weekly for the first month.

Does phentermine interact with tirzepatide? There is no pharmacokinetic interaction (neither medication changes the blood levels of the other). The concern is pharmacodynamic: both affect cardiovascular function, and the effects may add together. This is not a drug-drug interaction in the traditional sense but a physiological interaction.

Can I take phentermine if tirzepatide stops working? If you have been on tirzepatide for 9-12 months and weight loss has plateaued for 8+ weeks, short-term phentermine (8-12 weeks) may help restart progress. This is one of the few scenarios where combination therapy is considered. Discuss with your provider and ensure cardiovascular monitoring.

Is phentermine-topiramate (Qsymia) safer than phentermine alone with Mounjaro? Phentermine-topiramate is an FDA-approved combination with published safety data. However, combining Qsymia with tirzepatide has not been studied and would involve three weight-loss medications simultaneously, which is not standard practice. Most providers would choose either Qsymia or tirzepatide, not both.

What if I have high blood pressure already? Phentermine is contraindicated in uncontrolled hypertension. If your blood pressure is above 140/90 mmHg, do not take phentermine. Tirzepatide alone lowers blood pressure through weight loss and is a better choice for patients with hypertension.

Can I drink coffee while taking both medications? Caffeine is a mild stimulant that can add to phentermine's cardiovascular effects. If you are taking both medications, limit caffeine to 200 mg per day (about 2 cups of coffee) and avoid energy drinks. Monitor for increased heart rate or jitteriness.

What happens if I stop phentermine but continue tirzepatide? Most patients continue losing weight on tirzepatide alone after stopping phentermine. Tirzepatide's appetite suppression and metabolic effects are sustained as long as you remain on the medication. Phentermine's effects wear off within 48-72 hours of the last dose.

Are there any natural alternatives to phentermine that are safer with Mounjaro? No supplement has been proven to enhance tirzepatide's weight-loss effects. High-protein diets, resistance training, and adequate sleep all support weight loss and are safe to combine with tirzepatide. Avoid stimulant-containing supplements (caffeine pills, synephrine, yohimbine) for the same cardiovascular reasons phentermine is concerning.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Hendricks EJ et al. Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long-Term Phentermine Pharmacotherapy for Obesity. Obesity. 2011.
4. Aronne LJ et al. Continued Treatment With Phentermine/Topiramate Extended-Release in Adults With Obesity. Obesity. 2013.
5. Gadde KM et al. Effects of Low-Dose, Controlled-Release, Phentermine Plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER). Lancet. 2011.
6. Garvey WT et al. Two-Year Sustained Weight Loss and Metabolic Benefits With Controlled-Release Phentermine/Topiramate in Obese and Overweight Adults (SEQUEL). Obesity. 2012.
7. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002.
8. Bray GA et al. A 6-Month Randomized, Placebo-Controlled, Dose-Ranging Trial of Topiramate for Weight Loss in Obesity. Obesity Research. 2003.
9. Greenway FL et al. Effect of Naltrexone Plus Bupropion on Weight Loss in Overweight and Obese Adults (COR-I). Lancet. 2010.
10. Torgerson JS et al. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 2004.
11. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Tirzepatide in Patients With Type 2 Diabetes. Diabetes Care. 2023.
12. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
14. American College of Cardiology. Cardiovascular Risk Assessment in Weight-Loss Pharmacotherapy. Journal of the American College of Cardiology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Qsymia is a registered trademark of Vivus, Inc. Contrave is a registered trademark of Currax Pharmaceuticals LLC. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• Phentermine Online Prescription: What's Legal, What's Required, and What to Expect
• How to Get a Prescription for Mounjaro: The Complete 2026 Process for Brand and Compounded Tirzepatide
• How to Get Mounjaro for $25 a Month: The Real 2026 Savings Card Path